Founder
July 25th, 2006, 10:59 AM
The Baylor University Clinical Trial
From the time we first released X-Factor back in 2003, it was our ultimate goal to legitimize this powerful anabolic in the world of sports medicine. In order to be accepted here, a product must prove itself, not merely in anecdotal reports from users, but in published peer-reviewed clinical studies. Few sports supplements are ever put through the rigorous evaluation of an independent double blind University investigation, and fewer still have demonstrated true ergogenic benefits under the rigid standards of statistical analysis and scientific reproducibility. It is in the annals of respected Sports Medicine journals that a supplement’s true worth will shine through, or its deficiencies made clear.
Last year we put our product to the ultimate test, asking the Exercise & Sport Nutrition Laboratory at Baylor University to conduct one of the single most comprehensive investigations ever conducted on a sports nutrition product. The results were presented at the International Society of Sports Nutrition conference in June 2006, and represent a great success in demonstrating, in a clinical setting, the ergogenic potential of arachidonic acid. The data underlines the countless reports of increased muscle mass, strength, endurance and fat loss coming from competitive athletes and bodybuilders worldwide, and earns arachidonic acid a place next to a very select few clinically proven ergogenic nutrients.
Overview
The purpose of this double-blind placebo-controlled study was to determine if 50 days of resistance training and arachidonic acid (X-Factor™) supplementation would affect training adaptations in experienced (>1 year) resistance-trained males.
Protocol
Thirty-one subjects (22.1 ± 5.0 yrs) were randomly assigned to ingest either a placebo (n=16) or arachidonic acid [X-Factor] (n=15). All subjects ingested a total of four capsules each day by ingesting one 250mg capsule every four hours. Supplemental protein powder was provided in order attain a protein intake of 2 grams per kilogram of bodyweight per day. Each subject completed two upper-body and two lower-body workouts each week in a split-body fashion. Total training volumes were calculated from training logs. Body mass, body composition using DEXA, bench press one-repetition maximum (1RM), leg press 1RM and Wingate anaerobic capacity tests were completed at 0, 25 and 50 days. Data were analyzed using repeated measures ANOVA and are presented as mean ± SD changes from baseline after 50-days. Strength Results
Strength Results
Bench Press 1-Rep Max
During the clinical study, subjects taking X-Factor added an average of 25lbs to their bench press maximum weight in 50 days. This increase was nearly 45% greater than that noted in the exercise-only (placebo) group. Several subjects gained more than 50 lbs on their bench press 1-rep max over the 50-day period!
Muscular Power Results
Average Power
In the standard Wingate cycle ergometer test often used by professional athletes to measure anaerobic power and performance, the X-Factor group outperformed the placebo group on Average Power by an amazing 21 watts (AA: 37.9W P: 17.0W). That's a net increase of nearly 225% compared to placebo!
Wingate Peak Power Test
Using the standard Wingate cycle ergometer test to measure relative peak anaerobic power, subjects taking X-Factor increased leg power by 1.2 Watts•kg-1. This represents a net increase of more than 600% over the placebo group (-.2 Watts•kg-1).
Muscular Endurance Results
Total Work
Total Work, as recorded in the standard energy unit Joules, increased by 1,292J in the group taking X-Factor, while Total Work increased 510J in the placebo group. This is more than a 250% increase compared to placebo! This means more sets, more reps, and far more total workload capacity for those taking X-Factor!
Safety Results
Clinical Markers of Safety
No changes were noted in immune and serum clinical safety markers in subjects taking X-Factor. This included immune markers (white blood cell count, neutrophil count, lymphocyte count, and neutrophil: lymphocyte ratio), red blood cell count, hemoglobin concentration, hematocrit, liver enzymes (alanine aminotransferase, gamma-glutamyl transferase, serum albumin, and aspartate aminotransferase), and kidney function/catabolic indicators (blood urea nitrogen, creatinine, and BUN:creatinine ratio). The results demonstrated that X-Factor supplementation during an extended period of resistance training is physiologically well tolerated and does not alter whole blood, liver or kidney clinical safety markers.
Clinical Marker of Inflammation
The X-Factor group noted a significant decrease in serum levels of Interkeukin-6 (IL-6), a primary regulator and marker of inflammation in the body (AA: -28.8 P: 52.5). In addition to being “pro-inflammatory”, Interleukin-6 (IL-6) is the primary stimulus for the hepatic production of C-reactive protein, and is associated with a number of adverse health conditions including cardiovascular disease, diabetes, autoimmune disorder, rheumatoid arthritis, asthma, osteoporosis, and cancer.
X-Factor is SAFE
X-Factor supplementation during 50 days of resistance training did not negatively affect markers of immune function, inflammation, or general health and safety. Reductions in Interleukin-6 suggest it might, furthermore, offer a health-protective benefit by reducing systemic inflammation.
From the time we first released X-Factor back in 2003, it was our ultimate goal to legitimize this powerful anabolic in the world of sports medicine. In order to be accepted here, a product must prove itself, not merely in anecdotal reports from users, but in published peer-reviewed clinical studies. Few sports supplements are ever put through the rigorous evaluation of an independent double blind University investigation, and fewer still have demonstrated true ergogenic benefits under the rigid standards of statistical analysis and scientific reproducibility. It is in the annals of respected Sports Medicine journals that a supplement’s true worth will shine through, or its deficiencies made clear.
Last year we put our product to the ultimate test, asking the Exercise & Sport Nutrition Laboratory at Baylor University to conduct one of the single most comprehensive investigations ever conducted on a sports nutrition product. The results were presented at the International Society of Sports Nutrition conference in June 2006, and represent a great success in demonstrating, in a clinical setting, the ergogenic potential of arachidonic acid. The data underlines the countless reports of increased muscle mass, strength, endurance and fat loss coming from competitive athletes and bodybuilders worldwide, and earns arachidonic acid a place next to a very select few clinically proven ergogenic nutrients.
Overview
The purpose of this double-blind placebo-controlled study was to determine if 50 days of resistance training and arachidonic acid (X-Factor™) supplementation would affect training adaptations in experienced (>1 year) resistance-trained males.
Protocol
Thirty-one subjects (22.1 ± 5.0 yrs) were randomly assigned to ingest either a placebo (n=16) or arachidonic acid [X-Factor] (n=15). All subjects ingested a total of four capsules each day by ingesting one 250mg capsule every four hours. Supplemental protein powder was provided in order attain a protein intake of 2 grams per kilogram of bodyweight per day. Each subject completed two upper-body and two lower-body workouts each week in a split-body fashion. Total training volumes were calculated from training logs. Body mass, body composition using DEXA, bench press one-repetition maximum (1RM), leg press 1RM and Wingate anaerobic capacity tests were completed at 0, 25 and 50 days. Data were analyzed using repeated measures ANOVA and are presented as mean ± SD changes from baseline after 50-days. Strength Results
Strength Results
Bench Press 1-Rep Max
During the clinical study, subjects taking X-Factor added an average of 25lbs to their bench press maximum weight in 50 days. This increase was nearly 45% greater than that noted in the exercise-only (placebo) group. Several subjects gained more than 50 lbs on their bench press 1-rep max over the 50-day period!
Muscular Power Results
Average Power
In the standard Wingate cycle ergometer test often used by professional athletes to measure anaerobic power and performance, the X-Factor group outperformed the placebo group on Average Power by an amazing 21 watts (AA: 37.9W P: 17.0W). That's a net increase of nearly 225% compared to placebo!
Wingate Peak Power Test
Using the standard Wingate cycle ergometer test to measure relative peak anaerobic power, subjects taking X-Factor increased leg power by 1.2 Watts•kg-1. This represents a net increase of more than 600% over the placebo group (-.2 Watts•kg-1).
Muscular Endurance Results
Total Work
Total Work, as recorded in the standard energy unit Joules, increased by 1,292J in the group taking X-Factor, while Total Work increased 510J in the placebo group. This is more than a 250% increase compared to placebo! This means more sets, more reps, and far more total workload capacity for those taking X-Factor!
Safety Results
Clinical Markers of Safety
No changes were noted in immune and serum clinical safety markers in subjects taking X-Factor. This included immune markers (white blood cell count, neutrophil count, lymphocyte count, and neutrophil: lymphocyte ratio), red blood cell count, hemoglobin concentration, hematocrit, liver enzymes (alanine aminotransferase, gamma-glutamyl transferase, serum albumin, and aspartate aminotransferase), and kidney function/catabolic indicators (blood urea nitrogen, creatinine, and BUN:creatinine ratio). The results demonstrated that X-Factor supplementation during an extended period of resistance training is physiologically well tolerated and does not alter whole blood, liver or kidney clinical safety markers.
Clinical Marker of Inflammation
The X-Factor group noted a significant decrease in serum levels of Interkeukin-6 (IL-6), a primary regulator and marker of inflammation in the body (AA: -28.8 P: 52.5). In addition to being “pro-inflammatory”, Interleukin-6 (IL-6) is the primary stimulus for the hepatic production of C-reactive protein, and is associated with a number of adverse health conditions including cardiovascular disease, diabetes, autoimmune disorder, rheumatoid arthritis, asthma, osteoporosis, and cancer.
X-Factor is SAFE
X-Factor supplementation during 50 days of resistance training did not negatively affect markers of immune function, inflammation, or general health and safety. Reductions in Interleukin-6 suggest it might, furthermore, offer a health-protective benefit by reducing systemic inflammation.